Citadel Advisors »

Nektar Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Nektar Therapeutics (NKTR) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Nektar Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Nektar Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nektar Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $48M 849k 56.90
2025-06-30 $13M 496k 25.84

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Nektar Therapeutics

Susquehanna International
BVF
Vanguard Group
Citadel Advisors
Farallon Capital Management
BlackRock
Millennium Management
Two Sigma Investments
Nantahala Capital Management
22NW
Emerald Advisers
Leucadia National Corporation
Dr. Jeffrey R. Jay, M.D.
PRIMECAP Management Company
Renaissance Technologies

View all funds holding Nektar Therapeutics